Trials / Completed
CompletedNCT02418481
Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)
γδ T Cell Immunotherapy for Treatment of Breast Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In this study, effects of γδT cells on human breast cancer (her2-, er-,pr-) in combination with tumor reducing surgery, for example cryosurgery going to be investigated.
Detailed description
Breast tumor will be removed using tumor reducing surgery such as cryosurgery. PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as immunotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DC-CIK | DC-CIK cells will be used against tumor cells. |
| BIOLOGICAL | γδ T Cell | γδ T cells will be used against breast tumor. |
| BIOLOGICAL | Combination | γδ T/DC-CIK cells will be used against breast tumor. |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2015-04-16
- Last updated
- 2016-07-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02418481. Inclusion in this directory is not an endorsement.